Roche, I-Mab Biopharma Signs Agreement for Clinical Research

I-Mab Biopharma (“I-Mab”), a clinical stage biopharmaceutical company exclusively focused on the development of potential first-in-class and best-in-class biologics in immuno-oncology and autoimmune diseases enters into a collaboration with Roche for I-Mab`s clinical study to evaluate TJD5 in combination with atezolizumab (TECENTRIQ).

Roche will supply atezolizumab (TECENTRIQ) to I-Mab for use in clinical study in combination with TJD5. All rights generated in the study will belong jointly to I-Mab and Roche.

TJD5 is a proprietary innovative CD73 antibody from I-Mab`s discovery pipeline with best-in-class potential. CD73 is an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine, which contributes to a highly immunosuppressive tumor micro-environment. On January 18, 2019, TJD5 received IND clearance from the U.S. FDA.

https://www.marketscreener.com/ROCHE-HOLDING-68997/news/Roche-I-Mab-Biopharma-Signs-Agreement-for-Clinical-Research-of-TJD5-in-Combination-Therapy-28396883/